Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01326364

Enrollment

Registered

2011-03-30

Start date

2010-03-31

Completion date

2012-06-30

Last updated

2016-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Interventions

PROCEDUREStereotactic body radiotherapy

Standard of Care

DRUGIodixanol

IV, calculated per patient

DRUGIohexol

IV, Calculated per patient

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and 2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.

Exclusion criteria

1\) are absolute contraindications to intravenous iodinated contrast or CT scan.

Design outcomes

Primary

Measure	Time frame
Histological markers of tumor angiogenesis (microvessel density, EGF/VEGF expression level)	1 day
Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response)	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026